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ABSTRACT
Objectives: This study aims to describe salivary beta-2 microglobulin (sB2M) levels in our setting and to assess the performance of sB2M for the 
diagnosis of Sjögren's syndrome (SS).
Patients and methods: This cross-sectional, comparative study included 192 SS patients (2 males, 190 females; mean age 53.1 years; 
range 23 to 84 years) and 64 healthy controls (1 male, 63 females; mean age 46.9 years; range 21 to 82 years). Patients were divided into three groups 
as those with primary SS, secondary SS, and sicca non-Sjögren's syndrome (snSS). sB2M was measured by enzyme-linked immunosorbent assay in 
whole unstimulated saliva (ng/mL). Differences in sB2M were evaluated using the Kruskal-Wallis test. Receiver operating curves were generated to 
determine the performance of sB2M for distinguishing between SS and non-autoimmune snSS groups, and between SS group and healthy controls.
Results: The primary SS and secondary SS groups had a significantly higher concentration of sB2M than the other two groups. There was no 
significant difference in the concentration of sB2M between primary SS and secondary SS groups, and neither between snSS group and healthy 
controls. The receiver operating curve analysis for distinguishing SS and snSS showed an area under the curve of 0.661 (95% confidence interval 
0.590-0.728, p=0.0001) with an optimal cutoff value of 0.582 ng/mL. Sensitivity, specificity, positive predictive value, and negative predictive value 
were 68.7%, 59.3%, 20.2%, and 92.7%, respectively. The reported prevalence of SS in Mexico was considered when calculating the last two values.
Conclusion: In our setting, sB2M effectively distinguished between SS patients and non-autoimmune sicca symptoms. Including sB2M in our 
conventional diagnostic arsenal may assist in the evaluation of patients in whom SS is suspected; however, further studies are needed to clarify this 
hypothesis. 
Keywords: Beta-2 microglobulin; diagnosis; saliva; Sjögren’s syndrome.
Elevated salivary beta-2 microglobulin (sB2M) 
has been already reported in both primary 
Sjögren’s syndrome (pSS) and secondary SS 
(sSS).1,2 B2M is present on the plasmalemma of 
many cells, including infiltrating lymphocytes and 
salivary gland epithelial cells, and its increased 
levels in saliva may be related to salivary gland 
inflammatory activity in SS.3 Sialochemistry 
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has been proposed as a useful tool in SS.2,4 
Asashima et al.5 recently reported cutoff levels of 
sB2M for differentiating SS patients from other 
patients in a Japanese sample. To the best of our 
knowledge, sB2M levels are currently unknown 
in our population. Therefore, in this study, we 
aimed to describe sB2M levels in our setting 
and to assess the performance of sB2M for the 
diagnosis of SS.
PATIENTS AND METHODS
This cross-sectional, comparative study included 
192 SS patients (2 males, 190 females; mean 
age 53.1 years; range 23 to 84 years) recruited 
from the outpatient clinic between July 2012 
and July 2014 and 64 healthy controls (HC; 
1 male, 63 females; mean age 46.9 years; 
range 21 to 82 years). Patients were divided 
into three groups as those with pSS, sSS, and 
sicca non-Sjögren's syndrome (snSS) (each group 
n=64). HC were recruited from among staff and 
patients’ companions who were non-relatives. 
Of the SS patients, those with history of human 
immunodeficiency virus, hepatitis B and C, 
head and neck radiation therapy, sarcoidosis, 
amyloidosis, immunoglobulin G4-related disease, 
chronic kidney disease, lymphoma, or multiple 
myeloma were excluded. All conditions mentioned 
in this study were diagnosed according to their 
corresponding criteria.6-9 snSS was defined 
on clinical and laboratory grounds. None of 
these patients had a history of autoimmune 
disease. The study protocol was approved by the 
institutional review board. A written informed 
consent was obtained from all individuals. The 
study was conducted in accordance with the 
principles of the Declaration of Helsinki.
Beta-2 microglobulin was determined 
by an enzyme-linked immunosorbent assay 
(ab108885, Abcam, Cambridge, UK) and results 
were expressed as nanograms per milliliter 
(ng/mL). As noted in a previous report,10 our 
protocol was similar to that formerly described 
by Castro et al.4 Unstimulated whole saliva 
samples were collected at the fasting state, in 
the morning, by passive spitting into containers 
over 15 minutes. These samples were thus 
centrifuged at 14,000¥g for 20 minutes at +4°C 
prior to assaying.
Statistical analysis
The Kolmogorov-Smirnov test was used to 
evaluate whether the distribution of continuous 
variables was normal. Discrete variables were 
evaluated using exact r x c contingency table 
analysis or Chi-squared test. Continuous 
variables were evaluated using one-way analysis 
of variance or Kruskal-Wallis test. If the one-
way analysis of variance was positive, then 
the Student-Newman-Keuls test was performed 
for pairwise comparison of groups. If the 
Kruskal-Wallis test was positive, then a test for 
pairwise comparison of groups was performed 
according to Conover.11 Receiver operating 
characteristic (ROC) curves were generated 
to determine the performance of sB2M for 
distinguishing SS and snSS/HC. Sensitivity, 
specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were thus 
estimated. The reported prevalence of SS in 
Mexico was considered when calculating the last 
two values.12 Discrete variables are expressed as 
frequency counts and percentages. Continuous 
variables are expressed as mean ± standard 
deviation or median (P25, P75). Except for 
exact contingency table analysis, statistical 
analyses were performed using MedCalc for 
Windows, version 13.3 (MedCalc Software, 
Ostend, Belgium). Exact contingency table 
analysis was performed using Statistics to Use.13 
A p value of <0.05 was considered statistically 
significant. MedCalc was also used to generate 
the ROC curves. The boxplot was made using 
GraphPad Prism for Windows, version 5.01 
(GraphPad Software, San Diego, USA).
RESULTS
Healthy controls were younger than the other 
groups (p<0.05). Although there was no 
statistically significant difference in the distribution 
of sex between groups, the distribution of 
type 2 diabetes mellitus, arterial hypertension, 
and fibromyalgia was different between groups 
(p<0.015). There was no statistically significant 
difference in the proportion of users of steroids, 
xerogenic medication, and hydroxychloroquine 
between pSS and sSS groups. However, the use 
of methotrexate was more common in those with 
sSS (p=0.009) (Table 1).
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There was a statistically significant difference in 
sB2M levels between groups (p<0.000001). The 
pSS and sSS groups had a comparatively higher 
concentration of sB2M than the other two groups 
(p<0.005). There was no statistically significant 
difference in the concentration of sB2M between 
pSS and sSS groups, and neither between snSS 
group and HC (Table 2 and Figure 1a). The 
ROC curve analysis for distinguishing SS and 
snSS based on sB2M showed an area under the 
curve of 0.661 (95% confidence interval [CI]: 
0.590-0.728, p=0.0001) with an optimal cutoff 
value of 0.582 ng/mL (Figure 1b). Sensitivity, 
specificity, PPV, and NPV were 68.7% (95% 
CI: 60-76.6%), 59.3% (95% CI: 46.4-71.5%), 
20.2% (95% CI: 12.3-30.3%), and 92.7% (95% 
CI: 86-96.8%), respectively. The area under the 
curve for distinguishing SS and HC was 0.747 
(95% CI: 0.679-0.807, p<0.0001). At a cutoff 
level of 0.625 ng/mL, sensitivity, specificity, 
PPV, and NPV were 66.4% (95% CI: 57.5-74.5%), 
76.5% (95% CI: 64.3-86.2%), 29.7% (95% CI: 
18.2-43.5%), and 93.8% (95% CI: 88.4-97.2%), 
respectively (Figure 1c).
DISCUSSION
In this study, we found that B2M in whole 
unstimulated saliva can distinguish between SS 
and snSS, and also between SS and HC. In 
Mexico, a sB2M level below the cutoff can rule 
out this diagnosis (NPV >92%). PPV and NPV 
can be recalculated for different populations 
using some formulas based on Bayes' theorem 
(available in MedCalc). We also showed that sB2M 
can particularly distinguish pSS patients from 
those with sicca symptoms but no autoimmune 
disease.
Maddali Bongi et al.14 studied three decades 
ago the diagnostic performance of sB2M in a 
small sample. In this study, the diagnosis of pSS 
was established based on the criteria proposed by 
Fox et al.,15 which are no longer in use.14 Asashima 
et al.5 recently reported cutoff levels of sB2M for 
differentiating SS patients from other patients and 
HC in a Japanese sample. While on a first level 
our results were similar to theirs (i.e., sB2M was 
higher in pSS group compared to HC, and no 
difference between pSS and sSS groups), there 
were at least two relevant discrepancies between T
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them: (i) the magnitude of sB2M levels, and (ii) the 
results of the ROC curve.
Addressing the first point, they reported 
a mean level of sB2M of 5.3±4.6 mg/L 
(or 5,300±4,600 ng/mL) in those with pSS.5 
In our study, the highest concentration of sB2M 
was found in a pSS patient, but it was 9.1 ng/mL 
(or 0.0091 mg/L) (Figure 1a). As a matter of 
fact, we reported a median level of sB2M of 0.71 
(0.442, 1.175) ng/mL (or 0.00071 [0.000442, 
0.001175] mg/L) in those with pSS (Table 2). 
Although this disparity could be attributed to 
variations in salivary flow,16 it is not confined only 
to this group (i.e., pSS), and HC have no reason 
Table 2. Salivary beta-2 microglobulin (ng/mL) in whole unstimulated saliva
Individuals 64 64 50 14 64 64
Median 0.7109 0.76970 0.84450 0.63130 0.52780 0.35950
P25 0.4420 0.52620 0.62500 0.22890 0.27330 0.27190
P75 1.1756 1.29060 1.39090 0.88850 0.81530 0.62500
pSS: Primary Sjögren’s syndrome; sSS: Secondary Sjögren’s syndrome; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; snSS: Sicca 
non-Sjögren’s syndrome; HC: Healthy controls; P25: 25th percentile; P75: 75th percentile.
 pSS sSS sSS (RA)* sSS (SLE)* snSS HC
Figure 1. (a) Salivary beta-2 microglobulin in whole unstimulated saliva. (b) Performance 
characteristics of salivary beta-2 microglobulin for distinguishing Sjögren’s syndrome and sicca 
non-Sjögren’s syndrome, and (c) Sjögren’s syndrome and healthy controls. 95% confidence bounds 
for the receiver operating characteristic curves are also displayed.
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to have salivary flow alterations: Asashima et al.5 
reported a mean level of sB2M of 1.2±0.7 mg/L 
(or 1,200±700 ng/mL) in HC, while we reported 
a median level of 0.3595 (0.2719, 0.625) ng/mL 
(or 0.0003595 [0.0002719, 0.000625] mg/L) 
in the same group (Table 2). It is worth noting 
that, in measuring sB2M, different products 
were employed: they used a latex agglutination 
photometric immunoassay (Eiken Chemicals 
Co., Tokyo, Japan), and we used an in vitro 
enzyme-linked immunosorbent assay (ab108885, 
Abcam, Cambridge, UK), which was designed 
for the quantitative measurement of B2M levels 
in saliva and other fluids. We do not know if this 
latex agglutination photometric immunoassay 
was designed, or has been previously used, in 
saliva. Its pamphlet is not available in English 
(retrieved on September 29, 2016: http://www.
eiken.co.jp/products_technique/pamph/9009.
pdf). Asashima et al.17 previously reported the 
highest level of sB2M in the literature. In this 
case report, they used the same measurement 
method (i.e., latex agglutination photometric 
immunoassay).
Addressing the second point, on ROC curve 
analysis, Asashima et al.5 reported a sB2M cutoff 
level of 2.3 mg/L (2,300 ng/mL) to differentiate 
the SS group from the non-SS group. None of 
the individuals evaluated by us (including both 
patients and HC) reached this cutoff level. Due to 
the above, we did not recalculate PPV and NPV 
using their results.
Hu et al.18 previously proposed to study 
sB2M in order to distinguish patients with 
pSS from those with sicca symptoms but no 
autoimmune disease. Our snSS group represents 
such patients. Baldini et al.19 also included a 
snSS group in their study. Specifically addressing 
this point, the ROC curve analysis showed 
an area under the curve of 0.648 (95% CI: 
0.559-0.730, p=0.0023) with an optimal cutoff 
value of 0.638 ng/mL (not shown in Figure 1). 
Sensitivity, specificity, PPV, and NPV were 64% 
(95% CI: 51.1-75.7%), 60.94% (95% CI: 47.9-
72.9%), 4.8% (95% CI: 0.8-14.8%), and 98.2% 
(95% CI: 92.2-99.9%), respectively. In summary, 
in those with sicca symptoms and no history of 
autoimmune disease, a sB2M level below this 
cutoff can rule out the diagnosis of pSS (NPV 
>98%) in our setting.
Although our study was not underpowered, 
we did not find a statistically significant 
difference in sB2M between pSS and sSS 
groups. This is in contrast to the results from 
Baldini et al.19 but similar to that reported by 
Asashima et al.5 Unlike other investigators,5,18 
we only included patients with sicca symptoms, 
since the idea behind our study was to develop 
an additional tool to benefit in the diagnosis 
of those in whom SS is suspected (i.e., in 
those with sicca symptoms). In our study, 
fibromyalgia was more common in those with 
sicca symptoms but no autoimmune disease 
(snSS group). However, proteomic analysis of 
saliva has been already performed in patients 
with fibromyalgia and sB2M was not reported 
to be differentially expressed.20 Therefore, 
this difference in the proportion of patients 
with fibromyalgia probably did not influence 
our results. Previous studies with sB2M have 
used parotid saliva.2,3,21,22 Whole unstimulated 
saliva reflects the total contribution from all 
the salivary glands.16 As Asashima et al.,5 
we also employed unstimulated whole saliva, 
because this collection method is rapid, simple, 
inexpensive, and non-invasive, and it is thus 
more likely to be used in real-life clinical 
settings.
Our study has some limitations. For example, 
there were some baseline differences between 
groups. HC were comparatively younger than 
the rest of the groups. However, sB2M was not 
correlated with age in a previous study.22 The 
frequency of type 2 diabetes mellitus and arterial 
hypertension was also different between groups. 
However, as far as we know (and at least in 
PubMed/MEDLINE), there are no reports about 
the effect of diabetes mellitus (either type 1 or 2) 
or arterial hypertension on sB2M. Therefore, the 
possible influence of these two conditions on 
sB2M is currently unknown.
In conclusion, while sB2M may not be the 
ideal screening method for SS, it may be used 
as an adjunctive diagnostic test22 and, in our 
setting, it can effectively distinguish between SS 
patients (either pSS or sSS) and those with sicca 
symptoms but no autoimmune disease. Including 
sB2M in our conventional diagnostic arsenal may 
assist in the evaluation of patients in whom SS is 
suspected; however, further studies are needed to 
clarify this hypothesis.
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